Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Incos AB in connection with the sale of Scandinanvian Cosmetics AB
Mandate

Vinge advises Incos AB in connection with the sale of Scandinanvian Cosmetics AB

June 22, 2011

Vinge has advised the seller, Incos AB, in connection with the sale of Scandinavian Cosmetics AB together with its wholly owned subsidiary, BeautyCos AB, to the Valoras Group, which is listed in Switzerland.

Scandinavian Cosmetics AB and BeautyCos AB are Sweden's leading distributors of cosmetics, fragrances, skincare and haircare products. The companies market approximately 40 world leading trademarks within the beauty industry. The product portfolio includes Max Factor, Olay, Clarins, Kanebo/Sensai, Hugo Boss, Lacoste, Puma, Gucci, Escada, Bvlgari and Björn Axén. The companies have approximately 100 employees at offices in Malmö and Stockholm. In May this year, Scandinavian Cosmetics was awarded "Entrepreneur Company (South) 2011".

Vinge was the sole adviser and project manager in respect of the entire transaction. Vinge's team consisted of, among others, client relationship partner Lars Gildés and associates Christian Lindhé and Karolina Tjärnberg.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025